Healthcare technology companies, PicnicHealth announces clinical services offerings with virtual clinics designed for patients and virtual sites targeted at life sciences organizations.
The aim of these two services is to improve care management and facilitate more effective observational studies.
At the virtual clinic, patients will have access to the company’s universal patient record system as well as clinician support designed to help them manage their health more efficiently.
A universal patient record managed by PicnicHealth’s proprietary AI technology enables the company’s clinical care teams to evaluate patient history, identify gaps in care and gain actionable insights for patients.
Additionally, virtual clinics allow patients to interact directly with the company’s clinical care team to proactively discuss care recommendations and assist with follow-up care.
Meanwhile, PicnicHealth’s virtual site will enable life sciences companies to streamline observational research by exploring a wider range of study designs with new data collection methods.
For example, virtual sites unlock the ability to capture endpoints that aren’t recorded during routine care, expanding the company’s position in medical record integration.
The virtual site is supported by a research team of in-house clinicians and principal investigators to ensure proper study conduct.
“We’ve seen how challenging it can be to manage complex care journeys, so we designed our virtual clinic to simplify care by combining expert clinical guidance with technology,” Dr. Dan Drozd, Picnic Health’s chief medical officer, said in a statement.
“Virtual clinics provide a more consistent and supportive care experience, ensuring no part of a patient’s care is overlooked.”
Larger trends
In 2023, PicnicHealth has collaborated with AstraZeneca to establish a registry that uses patients’ medical records to generate real-world data to study stages 1-3 breast cancer.
same year, PicnicHealth has partnered with Genentech, a Roche subsidiary, to accelerate neurological disease research through investments in real-world data on Alzheimer’s disease and Alzheimer’s-related dementia and myasthenia gravis.
